首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   31262篇
  免费   4064篇
  国内免费   739篇
耳鼻咽喉   224篇
儿科学   1476篇
妇产科学   1011篇
基础医学   2996篇
口腔科学   642篇
临床医学   2668篇
内科学   3268篇
皮肤病学   391篇
神经病学   3923篇
特种医学   727篇
外国民族医学   6篇
外科学   2555篇
综合类   3335篇
一般理论   2篇
预防医学   2732篇
眼科学   5248篇
药学   2649篇
  16篇
中国医学   955篇
肿瘤学   1241篇
  2024年   26篇
  2023年   586篇
  2022年   790篇
  2021年   1287篇
  2020年   1487篇
  2019年   1433篇
  2018年   1416篇
  2017年   1573篇
  2016年   1480篇
  2015年   1306篇
  2014年   2179篇
  2013年   2498篇
  2012年   1878篇
  2011年   2038篇
  2010年   1655篇
  2009年   1388篇
  2008年   1470篇
  2007年   1390篇
  2006年   1323篇
  2005年   1099篇
  2004年   910篇
  2003年   869篇
  2002年   688篇
  2001年   618篇
  2000年   488篇
  1999年   421篇
  1998年   329篇
  1997年   302篇
  1996年   252篇
  1995年   235篇
  1994年   244篇
  1993年   215篇
  1992年   210篇
  1991年   193篇
  1990年   175篇
  1989年   160篇
  1988年   143篇
  1987年   121篇
  1986年   121篇
  1985年   194篇
  1984年   137篇
  1983年   109篇
  1982年   125篇
  1981年   105篇
  1980年   110篇
  1979年   59篇
  1978年   54篇
  1977年   47篇
  1976年   36篇
  1975年   30篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
《Survey of ophthalmology》2023,68(5):920-928
There remains limited agreement regarding the efficacy and safety of different antivascular endothelial growth factor (anti-VEGF) agents for the management of polypoidal choroidal vasculopathy (PCV). Our meta-analysis compares different anti-VEGF agents for PCV treatment. Ovid MEDLINE, EMBASE, and Cochrane Library were systematically searched from January 2000 to July 2022. We included articles comparing the efficacy and safety of different anti-VEGF agents, specifically bevacizumab (BEV), ranibizumab (RAN), aflibercept AFL), and brolucizumab (BRO), for patients with PCV. 10,440 studies were identified, 122 underwent full-text review, and seven were included. One study was a randomized trial, and six were observational studies. Ranibizumab and aflibercept were associated with a similar best-corrected visual acuity (BCVA) at the last visit in three observational studies (P = 0.10), similar retinal thickness at the last visit in two observational studies (P = 0.85). One observational study comparing BEV versus RAN found comparable outcomes for final BCVA, retinal thickness, and polyp regression. One randomized trial on BRO versus AFL found comparable outcomes for improvement in BCVA, while anatomical outcomes favored BRO. The available evidence suggests that final BCVA is comparable across different anti-VEGF agents, however, further investigation is warranted due to paucity of evidence.  相似文献   
2.
AIM: To investigate the clinical characteristics and genetic features of a Bietti crystalline dystrophy (BCD) proband in a Chinese family. METHODS: A Chinese female diagnosed with BCD complicated by bilateral choroidal neovascularization (CNV) and her parents underwent complete ophthalmic examinations, including fundus autofluorescence (AF), fundus photography (FP), fundus fluorescein angiography (FFA), visual field testing, full-field electroretinography (ERG), optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA). The sequencing of the CYP4V2 gene was performed to the whole family. RESULTS: Bilateral tiny glittering crystal-like deposits and differing extent of atrophy of the retinal pigment epithelium (RPE) were found in the posterior pole of her fundus. The diffuse hypo-fluorescence shown on AF images and window defects shown on FFA both indicated the atrophy of the RPE and choriocapillaris. OCT showed the thinning of the RPE and choriocapillaris layer, ellipsoid zone (EZ) band defect and CNV in both eyes. OCTA images proofed bilateral type 2 CNV. The visual field test showed central and paracentral scotoma. ERG showed a slightly decreased b-wave in scotopic ERG. Gene sequencing identified three mutations of the CYP4V2 gene, c.802_807del, c.810delT, and c.1388G>A. The mutation c.1388G>A was a novel substitution mutation. CONCLUSION: The novel mutation c.1388G>A may be a possible cause that could induce the clinical phenotype of BCD.  相似文献   
3.
目的:应用扫频光学相干断层扫描血管成像(SS-OCTA)对比研究白内障术中不同眼内压患者手术前后黄斑区血流的变化情况,为白内障个性化手术参数设计提供临床参考。

方法:前瞻性随机对照研究。收集2021-01/04于四川省人民医院住院行白内障手术的患者61例77眼,使用随机数字表分为A组(37眼)和B组(40眼),术中分别予以75、90cm灌注瓶瓶高,相当于55.5、66.6mmHg术中平均眼内压。所有患者除常规眼科检查外,术前、术后1、7、30d均行黄斑区SS-OCTA检查,观察黄斑区视网膜厚度及放射状毛细血管网(RPCP)层、浅层血管网(SVP)层、中层血管网(IVP)层、深层血管网(DVP)层灌注面积和血管密度。

结果:手术前后各时间点两组患者最佳矫正视力(BCVA)、眼压、黄斑中心凹无血管区(FAZ)面积、黄斑区视网膜厚度及各层灌注面积和血管密度均无组间差异性(均P>0.05),但均有时间差异性(均P<0.05),两组患者术后各时间点BCVA均较术前明显改善,眼压和FAZ面积均较术前下降(均P<0.05),黄斑区视网膜厚度及各层灌注面积和血流密度均较术前增加。

结论:白内障术后黄斑区视网膜厚度及各层血流密度和灌注面积均增加,FAZ面积下降,有助于促进术后视力的恢复,且术中选择55.5、66.6mmHg不同眼内压情况下,患者术后眼底血流改变情况无明显差异,故术中可以灵活选择眼内压,为患者提供个性化手术设计方案。  相似文献   

4.
王晨峰  卢旭华 《脊柱外科杂志》2022,20(5):322-326,333
目的 通过生物信息学分析椎间盘退行性变(IDD)相关的差异表达基因(DEG),寻找疾病的新型诊断标志物。方法 通过基因表达汇编(GEO)数据库GSE124272、GSE150408数据集下载IDD相关的外周血样本芯片数据,筛选出IDD组和正常组之间的DEG。使用DAVID在线数据库对DEG进行基因本体(GO)功能富集和京都基因与基因组百科全书(KEGG)信号通路富集,然后利用STRING在线数据库和Cytoscape软件构建蛋白质-蛋白质相互作用(PPI)网络并获取关键基因,并利用GSE23130数据集中的纤维环样本芯片数据进行验证。利用GSE124272、GSE150408数据集中的数据,采用受试者工作特征(ROC)曲线评估外周血中关键基因的诊断效能。结果 联合分析后筛选出597个DEG,包含363个上调基因和234个下调基因。GO功能富集分析发现DEG主要参与细胞黏附、细胞凋亡、趋化作用和细胞迁移等功能,KEGG分析发现DEG主要参与细胞外基质受体相互作用和癌症中的信号通路。PPI网络分析筛选出17个关键基因,经验证获得RBMX、EEF1A1、SSR1和POLR2C这4个基因,ROC曲线分析显示这4个基因对IDD诊断效能显著,曲线下面积分别为0.763、0.741、0.710、0.702。结论 RBMX、EEF1A1、SSR1和POLR2C或可成为IDD的新型诊断标志物,为该病进一步的功能研究提供理论依据。  相似文献   
5.
6.
IntroductionThis study was designed to assess whether a dental caries management protocol combining a single application of 38% silver diamine fluoride (SDF) with comprehensive oral health education will successfully divert high-risk children from dental treatment under dental general anaesthesia (DGA), arrest active caries in primary teeth, and improve parent-reported child oral health–related quality of life (OHRQoL).MethodsChildren aged 2 to 10 years, who attended two public dental agencies in Victoria, Australia, and were unable to tolerate restorative treatments in the clinic setting, elected to participate in either a 38% SDF intervention protocol or, alternatively, referral for DGA. Follow-up examinations were completed at 6 months to assess caries progression, decayed missing filled tooth index, PUFA index (pulpal involvement, ulceration, fistula, abscess), DGA referral rates, and OHRQoL (Early Childhood Oral Health Impact Scale [ECOHIS]).ResultsOf the total sample, 89.5% of children (n = 102) [mean (SD) age, 4.1 (1.0) years] with 401 active carious lesions elected to participate in the 38% SDF protocol; 10.5% (n = 12) of parents opted for referral for treatment under DGA. The proportion of active caries subsequently arrested at follow-up (number of arrested lesions/number of lesions treated) was 0.78 (95% CI, 0.69 to 0.87). There was an 88% reduction in referrals for DGA in eligible children over the 6-month period. The 38% SDF intervention group showed a significant improvement in ECOHIS scores at follow-up (P < .001).DiscussionAdoption of the 38% SDF intervention protocol resulted in a significant reduction in the rate of preventable dental hospitalisations. Most parents opted against referral for DGA. Parent-reported OHRQoL for children improved significantly.  相似文献   
7.
8.
陈莎  季杰  袁颖  姜凯  舒小华 《西部医学》2022,34(10):1487-1491
目的 探讨外周血淋巴细胞绝对计数(ALC)与老年弥漫大B细胞淋巴瘤(DLBCL)患者临床特征和R-CHOP方案化疗效果的关系。 方法 回顾性分析2017年1月~2021年2月广元市中心医院血液内科收治的老年DLBCL患者127例的相关资料,均经病理组织学确诊DLBCL且成功接受≥4个疗程R-CHOP方案化疗。依据DLBCL确诊时的ALC测定水平,将入选患者分成低ALC组(ALC<1.0×10 9/L,n=51)和高ALC组(ALC≥1.0×10 9/L,n=76),整理并比较两组系列临床特征指标的差异。依据化疗4个疗程后的疗效评估结果,将入选患者分成缓解组(完全缓解+部分缓解,CR+PR,n=92)和未缓解组(稳定+进展,SD+PD,n=35),并分析ALC水平与R-CHOP方案化疗效果的相关性。 结果 低ALC组临床分期Ⅲ~Ⅳ期、IPI评分3~5分的比重明显高于高ALC组(P<0.05),化疗前ALC水平与IPI评分呈明显负相关(r=-0.720,P<0.05)。低ALC组R-CHOP方案化疗缓解率明显低于高ALC组(P<0.05)。二元Logistic回归分析显示,临床分期Ⅲ~Ⅳ期(OR=1.691,95%CI:1.147~2.540)、IPI评分3~5分(OR=2.457,95% CI:1.561~3.713)和ALC<1.0×10 9/L(OR=1.803,95%CI:1.283~2.615)均是影响R-CHOP方案化疗效果的独立危险因素(P<0.05)。 结论 ALC不仅与老年DLBCL患者临床分期、病情危险分层紧密相关,而且ALC降低是影响R-CHOP方案化疗效果的危险因素。  相似文献   
9.
张俊友  轩安武  阮狄克 《中国骨伤》2022,35(11):1104-1108
颈椎前路椎间盘切除融合术(anterior cervical discectomy and fusion,ACDF)应用于临床近百年,取得了良好的临床疗效,被认为是治疗颈椎病的金标准。但融合术后邻近节段退变(adjacent segment degeneration,ASDeg)受到越来越多的关注,关于其发生机制的争论主要集中在融合术导致邻近节段生物应力的改变与年龄相关的自然退变。融合术后发生ASDeg将严重影响手术的中远期疗效,部分患者甚至需要二次手术治疗。为了降低甚至避免ASDeg的发生,临床上出现许多新的技术,诸如保留运动节段的人工椎间盘置换术,新兴的细胞移植技术等,但临床疗效仍需要大量的研究进行证实。因此,发现融合术后发生ASDeg的危险因素对于临床开展融合手术具有重要的意义。目前对于ASDeg危险因素的研究仍无统一认识,本文将从颈椎前路融合术后发生ASDeg的危险因素的研究进展及相应应对措施作一综述,以指导临床实践。  相似文献   
10.
AIM: To determine whether the prevalence of treated hypertension is higher among males or females with early/intermediate (e/i) age-related macular degeneration (AMD) with and without bilateral reticular pseudodrusen (RPD). METHODS: Retrospective review of the records of patients with e/iAMD who were recruited into the University of Colorado AMD registry between July 2014 and November 2019. Images were classified using the Beckman Initiative criteria and presence/absence of RPD. Patients were categorized into three groups: 1) e/iAMD with RPD; 2) e/iAMD without RPD; 3) control patients who did not have AMD. Multinomial logistic regression analysis was used for adjusted analysis with odds ratios (OR) and confidence intervals (CI). RESULTS: There were 260 patients with e/iAMD of which 101 had bilateral RPD and 159 had no RPD, and 221 controls. Overall, 62% of patients were female and the three groups did not differ by gender. When stratified by gender, the female e/iAMD/RPD group had a higher prevalence of hypertension, 64.1% vs 45.2% for controls, OR=2.2 (95%CI: 1.2-4.0). The frequency of hypertension in the e/iAMD/no RPD group was 54.1% and did not significantly differ from the control group. Among males, prevalence rates of treated hypertension did not differ. There is a significant interaction of hypertension and gender for the e/iAMD/RPD group such that women with e/iAMD who had RPD were significantly more likely to have hypertension (P=0.042). This relationship was not significant in the e/iAMD/no RPD group (P=0.269). CONCLUSION: Among females treated hypertension is significantly higher among e/iAMD/RPD patients, whereas for males there is no significant association.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号